Last reviewed · How we verify
Human serum albumin infusion 20%
At a glance
| Generic name | Human serum albumin infusion 20% |
|---|---|
| Also known as | VIALEBEX* 20% |
| Sponsor | Tianjin Huanhu Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Modulation of Cerebral Ischemia by Albumin (PHASE2)
- Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites (PHASE3)
- Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke (PHASE2)
- The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke (PHASE2)
- Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study) (PHASE3)
- Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells (PHASE2)
- Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D). (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human serum albumin infusion 20% CI brief — competitive landscape report
- Human serum albumin infusion 20% updates RSS · CI watch RSS
- Tianjin Huanhu Hospital portfolio CI